title: Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition.
abstract: BACKGROUND
  Cardiovascular disease is the leading cause of death worldwide, accounting for 30% of all deaths, with elevated blood pressure probably the most important modifiable risk factor. Worldwide, elevated blood pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all annual deaths. New drugs with different efficacy and effectiveness to control cardiovascular and renal disease are always welcomed.
  
  
  METHODS
  Adequate control of arterial hypertension is needed in order to reduce the consequences of cardiovascular and renal disease. A novel compound, LCZ696 , is currently in development based on the concept of comprising in the same entity a Neprilysin inhibitor, with a renin-angiotensin-aldosterone system inhibitor, in this case an angiotensin receptor blocker. This review, performed in PubMed including the last five years under the keywords cited below, presents the available data about LCZ696, the first-in-class angiotensin receptor Neprilysin inhibitor.
  
  
  CONCLUSIONS
  Available data show that positive efficacy and a good tolerability profile of LCZ696 in the treatment of arterial hypertension as well as preliminary data indicate that it can also be useful in the treatment of cardiovascular disease. These data are particularly promising in the treatment of arterial hypertension.
authors.affiliation: Hospital 12 de Octubre, Department of Nephrology, Hypertension Unit , Av. Córdoba s/n, 28041 Madrid, Spain.
authors.forename: Julian
authors.initials: J
authors.lastname: Segura
authors.forename: Jorge
authors.initials: J
authors.lastname: Salazar
authors.forename: Luis M
authors.initials: LM
authors.lastname: Ruilope
mesh_terms: D000613:Aminobutyrates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D001713:Biphenyl Compounds; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D006801:Humans; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D018377:Neurotransmitter Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013777:Tetrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D018377:Neurotransmitter Agents; D013777:Tetrazoles; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination